相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy
F. Grossi et al.
BRITISH JOURNAL OF CANCER (2017)
PD-1 and its ligands are important immune checkpoints in cancer
Yinan Dong et al.
ONCOTARGET (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis
Kentaro Inamura et al.
LUNG CANCER (2017)
Prognostic role of B7-H4 in patients with non-small cell lung cancer: A meta-analysis
Zhibo Tan et al.
ONCOTARGET (2017)
PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
Enrico Munari et al.
ONCOTARGET (2017)
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
Marco A. J. Iafolla et al.
FRONTIERS IN ONCOLOGY (2017)
Understanding the checkpoint blockade in lung cancer immunotherapy
Maria Giovanna Dal Bello et al.
DRUG DISCOVERY TODAY (2017)
B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes
Mehmet Altan et al.
CLINICAL CANCER RESEARCH (2017)
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
M. Ilie et al.
ANNALS OF ONCOLOGY (2016)
Programmed Death Ligand-1 Immunohistochemistry Friend or Foe?
Keith M. Kerr et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
B7-H3 Overexpression Predicts Poor Survival of Cancer Patients: A Meta-Analysis
Zhimeng Ye et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2016)
A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform
Tzahi Neuman et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer
Hong Xu et al.
ONCOLOGY LETTERS (2016)
Prognostic significance of B7-H4 expression in matched primary pancreatic cancer and liver metastases
Yun Qian et al.
ONCOTARGET (2016)
Prognostic role of high B7-H4 expression in patients with solid tumors: a meta-analysis
Xing Song et al.
ONCOTARGET (2016)
Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer
Shanshan Wu et al.
ONCOTARGET (2016)
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Claud Grigg et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non-Small Cell Lung Cancer
Therese Phillips et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2015)
B7-H1 and B7-H4 expression in colorectal carcinoma: Correlation with tumor FOXP3+ regulatory T-cell infiltration
Li-wei Zhao et al.
ACTA HISTOCHEMICA (2014)
B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look
Jenessa B. Smith et al.
GYNECOLOGIC ONCOLOGY (2014)
B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas
Xin Wang et al.
HUMAN IMMUNOLOGY (2014)
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
Yanping Xiao et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
The Inhibitory Role of B7-H4 in Antitumor Immunity: Association with Cancer Progression and Survival
Changjun He et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2011)
B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction
Judith Leitner et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
The B7 family and cancer therapy: Costimulation and coinhibition
Xingxing Zang et al.
CLINICAL CANCER RESEARCH (2007)
Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma
Ilona Kryczek et al.
CANCER RESEARCH (2007)
Murine B7-H3 is a negative regulator of T cells
DVR Prasad et al.
JOURNAL OF IMMUNOLOGY (2004)
Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family
IH Choi et al.
JOURNAL OF IMMUNOLOGY (2003)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
B7-H3:: A costimulatory molecule for T cell activation and IFN-γ production
AI Chapoval et al.
NATURE IMMUNOLOGY (2001)
分享论文
